The accreditation extends through February 2013.

This decision represents the best level of accreditation which can be awarded to a business and shows Jefferson’s considerable conformance to the CARF criteria. An organization receiving a Three-Calendar year Accreditation has put itself through a rigorous peer review procedure and has demonstrated to a team of surveyors during an on-site visit that its programs and providers are of the best quality, measurable, and accountable. This accreditation validates Jefferson’s standing as one of the premiere places for individuals seeking rehabilitative assistance in Philadelphia and through the entire Delaware Valley, stated John Melvin, M.D., chair, Department of Rehabilitation Medicine at Jefferson Medical University of Thomas Jefferson University... PRESS RELEASE NEW YORK & TAMPA, Fla.—-Bristol-Myers Squibb Firm and Moffitt Cancers Center today announced that they have entered right into a collaboration agreement as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy plan in the U.S. The I-O RPM system is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with risky, poor prognostic cancers, defined as a rare populace malignancy. As part of the I-O RPM program, Bristol-Myers Squibb and Moffitt will conduct a variety of early phase clinical studies, including scientific investigations by youthful investigators to reinforce their advancement as clinical research scientists.

Other entries from category "hematology":

Random entries